- "Considering its recent past, any progress would be an improvement," FierceBiotech's Damian Garde writes, referring to comments made by Merck KGaA (MKGAF) CEO Karl-Ludwig Kley which seem to indicate that the German drugmaker is open to acquisitions across its four business units.
- "We have four sustainable business divisions that are set to grow organically, but for all four areas we have ideas for steps that go beyond that," Kley tells the media.
- Garde notes that "repeated clinical failures" have left analysts jaded, but innovative ideas like development program cost-sharing could brighten the Erbitux maker's outlook even in the midst of "an R&D diet."
- See also: German Merck lifts guidance.
German Merck hints at M&A across divisions
Nov 14 2013, 12:18 ET